These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 30692044

  • 1. Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression.
    Chou FJ, Chen Y, Chen D, Niu Y, Li G, Keng P, Yeh S, Chang C.
    EBioMedicine; 2019 Feb; 40():504-516. PubMed ID: 30692044
    [Abstract] [Full Text] [Related]

  • 2. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9® to Suppress Enzalutamide-resistant Prostate Cancer Progression.
    Wang R, Sun Y, Li L, Niu Y, Lin W, Lin C, Antonarakis ES, Luo J, Yeh S, Chang C.
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [Abstract] [Full Text] [Related]

  • 3. ASC-J9® suppresses prostate cancer cell invasion via altering the sumoylation-phosphorylation of STAT3.
    Lin W, Luo J, Sun Y, Lin C, Li G, Niu Y, Chang C.
    Cancer Lett; 2018 Jul 01; 425():21-30. PubMed ID: 29425687
    [Abstract] [Full Text] [Related]

  • 4. Androgen receptor (AR) degradation enhancer ASC-J9® in an FDA-approved formulated solution suppresses castration resistant prostate cancer cell growth.
    Cheng MA, Chou FJ, Wang K, Yang R, Ding J, Zhang Q, Li G, Yeh S, Xu D, Chang C.
    Cancer Lett; 2018 Mar 28; 417():182-191. PubMed ID: 29203251
    [Abstract] [Full Text] [Related]

  • 5. Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9® led to increase docetaxel sensitivity via suppressing the p21 expression.
    Luo J, Tian J, Chou F, Lin C, Xing EZ, Zuo L, Niu Y, Yeh S, Chang C.
    Cancer Lett; 2019 Mar 01; 444():35-44. PubMed ID: 30248372
    [Abstract] [Full Text] [Related]

  • 6. ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals.
    Wen S, Tian J, Niu Y, Li L, Yeh S, Chang C.
    Cancer Lett; 2016 Jul 01; 376(2):377-86. PubMed ID: 27045473
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling.
    Tian H, Chou FJ, Tian J, Zhang Y, You B, Huang CP, Yeh S, Niu Y, Chang C.
    J Exp Clin Cancer Res; 2021 Jan 04; 40(1):3. PubMed ID: 33390173
    [Abstract] [Full Text] [Related]

  • 10. Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells.
    Wen S, Niu Y, Lee SO, Yeh S, Shang Z, Gao H, Li Y, Chou F, Chang C.
    Mol Carcinog; 2016 Dec 04; 55(12):2278-2290. PubMed ID: 26894509
    [Abstract] [Full Text] [Related]

  • 11. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
    Wang R, Lin W, Lin C, Li L, Sun Y, Chang C.
    Cancer Lett; 2016 Aug 28; 379(1):154-60. PubMed ID: 27233475
    [Abstract] [Full Text] [Related]

  • 12. ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.
    Yamashita S, Lai KP, Chuang KL, Xu D, Miyamoto H, Tochigi T, Pang ST, Li L, Arai Y, Kung HJ, Yeh S, Chang C.
    Neoplasia; 2012 Jan 28; 14(1):74-83. PubMed ID: 22355276
    [Abstract] [Full Text] [Related]

  • 13. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
    Lin TH, Lee SO, Niu Y, Xu D, Liang L, Li L, Yeh SD, Fujimoto N, Yeh S, Chang C.
    J Biol Chem; 2013 Jul 05; 288(27):19359-69. PubMed ID: 23687298
    [Abstract] [Full Text] [Related]

  • 14. Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression.
    Shang Z, Li Y, Zhang M, Tian J, Han R, Shyr CR, Messing E, Yeh S, Niu Y, Chang C.
    Mol Cancer Ther; 2015 Nov 05; 14(11):2586-94. PubMed ID: 26264279
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A review of the effects and molecular mechanisms of dimethylcurcumin (ASC-J9) on androgen receptor-related diseases.
    Hu H, Zhou H, Xu D.
    Chem Biol Drug Des; 2021 Apr 05; 97(4):821-835. PubMed ID: 33277796
    [Abstract] [Full Text] [Related]

  • 18. SIRT7 depletion inhibits cell proliferation and androgen-induced autophagy by suppressing the AR signaling in prostate cancer.
    Ding M, Jiang CY, Zhang Y, Zhao J, Han BM, Xia SJ.
    J Exp Clin Cancer Res; 2020 Feb 04; 39(1):28. PubMed ID: 32019578
    [Abstract] [Full Text] [Related]

  • 19. Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals.
    Deng G, Wang R, Sun Y, Huang CP, Yeh S, You B, Feng C, Li G, Ma S, Chang C.
    Cell Death Differ; 2021 Jul 04; 28(7):2145-2159. PubMed ID: 34127806
    [Abstract] [Full Text] [Related]

  • 20. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
    Guo C, Yeh S, Niu Y, Li G, Zheng J, Li L, Chang C.
    Cancer Lett; 2017 Jul 01; 397():133-143. PubMed ID: 28323036
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.